methylprednisolone
Trade name: medrol
Small moleculeapproved
Approved
Oct 24, 1957
Methylprednisolone is a prednisolone derivative with similar anti-inflammatory and immunosuppressive action. It is adjunctive therapy for short-term administration in rheumatoid arthritis. It is indicated in the following conditions: endocrine disorders, rheumatic disorders, collagen diseases, allergic states etc. Methylprednisolone is marketed in the USA and Canada under the brand names Medrol and Solu-Medrol. Methylprednisolone is a GR receptor agonist. — NCATS
Clinical trial activity
907 trials · 665 clinical orgs · 46 marketing orgs
Phase 1
122
Phase 2
454
Phase 3
236
Phase 4
195
Earliest trial started Mar 1, 1988 (NCT01177371)
Timeline
1950s
- Oct 24, 1957
Pharmacia & Upjohn — Earliest FDA Approval
- Oct 24, 1957
Pharmacia & Upjohn — NDA Secondary Org
- Oct 24, 1957
Pharmacia & Upjohn — NDA Organization
- Oct 24, 1957
Pfizer — Marketing Organization
- Oct 24, 1957
Pfizer — NDA Secondary Org
1960s
- Dec 7, 1964
Pharmacia & Upjohn — Marketing Organization
1970s
- Mar 28, 1978
Hospira — Marketing Organization
- Dec 6, 1979
Belmar Pharmacy — Marketing Organization
1980s
- Feb 15, 1980
Elkins Sinn — Marketing Organization
- Jul 28, 1981
Invatech — Marketing Organization
- Jul 28, 1981
Sandoz — Marketing Organization
- Jul 28, 1981
Rising Pharmaceuticals — Marketing Organization
- Feb 9, 1982
Watson Pharmaceuticals — Marketing Organization
- Jun 25, 1982
Organon — Marketing Organization
- Feb 21, 1984
Duramed Research — Marketing Organization
- Jun 8, 1984
Abraxis — Marketing Organization
- Jan 1, 1988
Earliest Phase 2 Sponsor(trial)
- Jan 1, 1988
Earliest Phase 3 Sponsor(trial)
- Apr 25, 1988
Par Pharmaceuticals — Marketing Organization
1990s
- Feb 22, 1991
Abbott — Marketing Organization
- Jan 1, 1994
Earliest Phase 1 Sponsor(trial)
- Oct 31, 1997
Jubilant Innovation Ltd. — Marketing Organization
- Oct 31, 1997
Novartis — Marketing Organization
- Dec 22, 1998
Endo Pharmaceuticals — Marketing Organization
- Dec 22, 1998
Vintage — Marketing Organization
- Dec 22, 1998
PH HEALTH — Marketing Organization
2000s
- Jul 30, 2004
Fresenius — Marketing Organization
- Feb 23, 2005
Teva — Marketing Organization
- Feb 23, 2005
Eu Yan Sang — Marketing Organization
- Feb 21, 2007
Bedford Pharmaceuticals — Marketing Organization
2010s
- Dec 15, 2015
Aurobindo Pharma — Marketing Organization
- Dec 15, 2015
Eugia Pharma — Marketing Organization
- Feb 16, 2016
Hikma — Marketing Organization
- Apr 23, 2018
Zydus Discovery DMCC — Marketing Organization
- May 14, 2018
Tianjin Tianyao Pharmaceuticals — Marketing Organization
- Jun 27, 2018
Sagent Pharmaceuticals, Inc. — Marketing Organization
- Jun 27, 2018
Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization
- Jan 9, 2019
Novast Labs — Marketing Organization
- Jan 9, 2019
RiconPharma — Marketing Organization
- Jan 9, 2019
Ingenus Pharmaceuticals — Marketing Organization
- Feb 22, 2019
Lupin — Marketing Organization
- Feb 22, 2019
Chartwell Pharmaceuticals — Marketing Organization
- May 20, 2019
Amneal Pharmaceuticals — Marketing Organization
- Jun 27, 2019
Praxgen Pharma — Marketing Organization
2020s
- Apr 20, 2021
Tianjin Kingyork — Marketing Organization
- Jan 21, 2022
Bristol-Myers Squibb — Marketing Organization
- Jan 3, 2023
Wilshire Pharmaceuticals — Marketing Organization
- Jan 3, 2023
Slayback Pharma Llc — Marketing Organization
- Jan 26, 2026
Caplin Point Laboratories — Marketing Organization
Indications
Approved for
- Adrenal Hyperplasia, Congenital (approved 1957)
- Anemia
- Arthritis, Juvenile
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Asthma
- Brain Neoplasms
- Bursitis
- Colitis, Ulcerative
- Communicable Diseases
- Crohn Disease
- Dermatitis
- Dermatitis, Atopic
- Dermatitis, Contact (approved 1957)
- Endocrine System Diseases
- Inflammation
- Leukemia
- Lymphoma
- Multiple Sclerosis
- Nephrotic Syndrome
- Osteoarthritis
- Pneumonia
- Serum Sickness
- Tenosynovitis
- Uveitis
- Uveitis, Posterior
Studied for
- Abdominal Pain · Phase 3
- Acute Kidney Injury · Phase 2/Phase 3
- Acute Lung Injury · Phase 2/Phase 3
- Acute-On-Chronic Liver Failure · Phase 3
- Adenovirus Infections, Human · Phase 3
- Administration, Intranasal · Phase 2
- Adrenal Cortex Hormones · Phase 4
- Adrenal Insufficiency · Phase 4
- Aging · Phase 3
- Airway Management · Phase 4
- Allergy and Immunology · Phase 4
- Allografts · Phase 3
- Alopecia · Phase 4
- Alveolitis, Extrinsic Allergic · Phase 4
- Amyotrophic Lateral Sclerosis · Phase 2
- Analgesics, Opioid · Phase 3
- Anemia, Aplastic · Phase 2/Phase 3
- Anemia, Diamond-Blackfan · Phase 2
- Anemia, Sickle Cell · Phase 3
- Anesthesia · Phase 4
- Ankle Injuries · Phase 2
- Antibodies, Antineutrophil Cytoplasmic · Phase 1/Phase 2
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 3
- Anxiety Disorders · Phase 3
- Aortic Dissection · Phase 4
- Aortic Valve Disease · Phase 4
- Aortic Valve Stenosis · Phase 4
- Aphasia · Phase 3
- Appendicitis · Phase 2
- Arrhythmias, Cardiac · Early Phase 1
- Arterial Occlusive Diseases · Phase 3
- Arthralgia · Phase 4
- Arthritis · Phase 3
- Arthritis, Juvenile · Phase 3
- Arthritis, Psoriatic · Phase 4
- Arthroplasty · Phase 4
- Arthroplasty, Replacement, Knee · Phase 4
- Asthma · Phase 4
- Atherosclerosis · Phase 1/Phase 2
- Atrial Fibrillation · Phase 4
- Autoimmune Diseases · Phase 2/Phase 3
- Back Pain · Phase 3
- Behcet Syndrome · Phase 4
- Biological Availability · Phase 1
- Bleeding Time · Phase 3
- Body Fat Distribution · Phase 1/Phase 2
- Bone Marrow Failure Disorders · Phase 2
- Bone Marrow Transplantation · Phase 2
- Brain Diseases · Phase 2
- Brain Injuries, Traumatic · Phase 4
- Breast Neoplasms · Phase 4
- Bronchopulmonary Dysplasia · Phase 3
- Bundle-Branch Block · Phase 4
- Burkitt Lymphoma · Phase 2
- Bursitis · Phase 4
- Carcinoma · Phase 2
- Carcinoma, Giant Cell · Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 2
- Carcinoma, Renal Cell · Phase 2
- Cardiac Surgical Procedures · Phase 4
- Cardiopulmonary Bypass · Phase 4
- Cardiovascular Diseases · Phase 3
- Carpal Tunnel Syndrome · Phase 4
- Charcot-Marie-Tooth Disease · Phase 2/Phase 3
- Chemical and Drug Induced Liver Injury · Phase 4
- Chemical and Drug Induced Liver Injury, Chronic · Phase 1/Phase 2
- Child · Phase 4
- Chondrocalcinosis · Phase 2
- Chronic Kidney Disease-Mineral and Bone Disorder · Phase 4
- Chronic Pain · Phase 4
- Churg-Strauss Syndrome · Phase 4
- Cluster Headache · Phase 4
- Colitis · Phase 3
- Colitis, Ulcerative · Phase 4
- Colorectal Neoplasms · Phase 1
- Colorectal Surgery · Phase 2
- Community-Acquired Infections · Phase 4
- Connective Tissue Diseases · Phase 2
- Constriction, Pathologic · Phase 3
- Contusions · Phase 4
- Coronary Aneurysm · Phase 3
- Coronary Artery Disease · Phase 1/Phase 2
- Coronary Disease · Phase 2
- Coronavirus · Phase 2
- Coronavirus Infections · Phase 4
- COVID-19 · Phase 4
- Cranial Nerve Diseases · Phase 1/Phase 2
- Cytokine Release Syndrome · Phase 4
- Cytomegalovirus Infections · Phase 4
- Deglutition Disorders · Phase 3
- Dementia · Phase 3
- Demyelinating Diseases · Phase 4
- Depression · Phase 3
- Dermatitis, Allergic Contact · Phase 1/Phase 2
- Dermatitis, Atopic · Phase 4
- Dermatomyositis · Phase 2
- Diabetes Complications · Phase 2/Phase 3
- Diabetes Mellitus · Phase 2
- Diabetes Mellitus, Type 1 · Phase 1/Phase 2
- DiGeorge Syndrome · Phase 1/Phase 2
- Drainage · Phase 4
- Drug Evaluation · Phase 4
- Drug Hypersensitivity Syndrome · Early Phase 1
- Drug Interactions · Phase 4
- Drug-Related Side Effects and Adverse Reactions · Phase 4
- Drug Resistant Epilepsy · Phase 1/Phase 2
- Drugs, Investigational · Phase 4
- Dry Eye Syndromes · Phase 3
- Dyskeratosis Congenita · Phase 2/Phase 3
- Eczema · Phase 1
- Edema · Phase 4
- Encephalitis, Viral · Phase 4
- Enteropathy-Associated T-Cell Lymphoma · Phase 2
- Erythema Multiforme · Phase 3
- Erythropoietin · Phase 2/Phase 3
- Esophageal Diseases · Phase 4
- Esophageal Neoplasms · Phase 4
- Esophageal Stenosis · Phase 2
- Facial Nerve Injuries · Early Phase 1
- Facial Paralysis · Phase 3
- Fallopian Tube Neoplasms · Phase 2
- Fanconi Anemia · Phase 2
- Fasciitis, Plantar · Phase 4
- Fatigue · Phase 4
- Fever · Early Phase 1
- Finger Injuries · Phase 2/Phase 3
- Foot Injuries · Phase 2
- Fractures, Bone · Phase 4
- Fractures, Closed · Phase 1
- Friedreich Ataxia · Early Phase 1
- Ganglion Cysts · Phase 1/Phase 2
- Gaucher Disease · Phase 1/Phase 2
- General Surgery · Phase 4
- Gestational Trophoblastic Disease · Phase 2
- Giant Cell Arteritis · Phase 2
- Glioma · Phase 1
- Glomerulonephritis · Phase 2/Phase 3
- Glomerulonephritis, IGA · Phase 4
- Glomerulonephritis, Membranous · Phase 3
- Glucocorticoids · Phase 4
- Gout · Phase 2/Phase 3
- Graft Rejection · Phase 4
- Graft vs Host Disease · Phase 3
- Granuloma · Phase 4
- Granulomatosis with Polyangiitis · Phase 4
- Graves Disease · Phase 4
- Graves Ophthalmopathy · Phase 4
- Guillain-Barre Syndrome · Phase 4
- Hamartoma · Phase 2
- Hand Injuries · Phase 2/Phase 3
- Hantavirus Infections · Phase 2
- Headache · Phase 4
- Head and Neck Neoplasms · Phase 1
- Healthy Volunteers · Phase 4
- Hearing Loss, Noise-Induced · Phase 1/Phase 2
- Hearing Loss, Sensorineural · Phase 4
- Hearing Loss, Sudden · Phase 4
- Heart Arrest · Phase 4
- Heart Block · Phase 4
- Heart Diseases · Phase 4
- Heart Transplantation · Phase 4
- Hemangioma · Phase 3
- Hematologic Neoplasms · Phase 3
- Hematoma, Subdural, Chronic · Phase 3
- Hematopoietic Stem Cell Transplantation · Phase 2
- Hemodynamics · Phase 4
- Hemophilia A · Phase 3
- Hepatic Encephalopathy · Phase 2
- Hepatic Insufficiency · Phase 4
- Hepatitis, Alcoholic · Phase 3
- Hepatitis, Autoimmune · Phase 4
- Hernia · Phase 3
- Herpesvirus 4, Human · Phase 3
- Histiocytosis, Langerhans-Cell · Phase 2
- HIV · Phase 2
- HIV Infections · Phase 3
- Hodgkin Disease · Phase 2
- Hyperalgesia · Phase 2
- Hypercholesterolemia · Phase 4
- Hyperlipoproteinemia Type I · Phase 2/Phase 3
- Hyperplasia · Phase 2
- Hyperuricemia · Phase 1
- Hypoadrenocorticism, Familial · Phase 4
- Hysterectomy · Phase 4
- Idiopathic Pulmonary Fibrosis · Phase 3
- IgA Vasculitis · Phase 4
- Immune Reconstitution Inflammatory Syndrome · Phase 4
- Immune System Diseases · Phase 2
- Immunity, Innate · Early Phase 1
- Immunocompromised Host · Phase 3
- Immunoglobulin G4-Related Disease · Phase 2
- Immunosuppression Therapy · Phase 4
- Immunosuppressive Agents · Phase 3
- Infections · Phase 3
- Inflammation · Phase 4
- Inflammatory Bowel Diseases · Phase 1
- Influenza A virus · Phase 3
- Influenza, Human · Phase 3
- Intervertebral Disc Degeneration · Phase 3
- Intestinal Neoplasms · Phase 2
- Intestinal Obstruction · Phase 2
- Intraocular Lymphoma · Phase 2
- Intussusception · Phase 1/Phase 2
- Ischemic Stroke · Phase 4
- Joint Diseases · Phase 4
- Kidney Diseases · Phase 3
- Kidney Failure, Chronic · Phase 4
- Kidney Transplantation · Phase 4
- Knee Injuries · Phase 2
- Labor Pain · Early Phase 1
- Language Disorders · Phase 3
- Laryngeal Diseases · Phase 3
- Laryngeal Edema · Phase 2
- Laryngostenosis · Phase 4
- Laser Therapy · Early Phase 1
- Leg Injuries · Phase 3
- Leukemia · Phase 3
- Leukemia, Large Granular Lymphocytic · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 3
- Leukemia, Lymphoid · Phase 3
- Leukemia-Lymphoma, Adult T-Cell · Phase 2
- Leukemia, Monocytic, Acute · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 3
- Leukemia, Myeloid, Acute · Phase 2
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1/Phase 2
- Leukemia, Myeloid, Chronic-Phase · Phase 2
- Leukemia, Myelomonocytic, Acute · Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 2
- Leukemia, Myelomonocytic, Juvenile · Phase 2
- Leukemia, Prolymphocytic · Phase 2
- Leukoencephalopathy, Progressive Multifocal · Phase 4
- Ligaments, Articular · Phase 4
- Liver Cirrhosis · Phase 4
- Liver Cirrhosis, Biliary · Phase 4
- Liver Diseases · Phase 4
- Liver Failure · Phase 4
- Liver Failure, Acute · Phase 4
- Liver Neoplasms · Phase 2
- Liver Transplantation · Phase 4
- Low Back Pain · Phase 4
- Lung Diseases · Phase 3
- Lung Diseases, Interstitial · Phase 4
- Lung Injury · Phase 3
- Lung Neoplasms · Phase 2
- Lung Transplantation · Phase 2
- Lupus Erythematosus, Systemic · Phase 4
- Lupus Nephritis · Phase 4
- Lymphohistiocytosis, Hemophagocytic · Phase 3
- Lymphoma · Phase 3
- Lymphoma, AIDS-Related · Phase 2
- Lymphoma, B-Cell · Phase 2
- Lymphoma, B-Cell, Marginal Zone · Phase 2
- Lymphoma, Follicular · Phase 4
- Lymphoma, Large B-Cell, Diffuse · Phase 3
- Lymphoma, Large-Cell, Anaplastic · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2/Phase 3
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 2
- Lymphoma, T-Cell · Phase 2
- Lymphoma, T-Cell, Peripheral · Phase 2
- Lymphomatoid Granulomatosis · Phase 2
- Lymphoproliferative Disorders · Phase 2
- Macrophage Activation Syndrome · Phase 3
- Macular Edema · Phase 2
- Magnetic Resonance Imaging · Phase 2
- Mastectomy · Phase 4
- Melanoma · Phase 2
- Memory Disorders · Phase 1/Phase 2
- Meniere Disease · Phase 3
- Metabolic Side Effects of Drugs and Substances · Phase 2
- Methylprednisolone · Phase 4
- Microscopic Polyangiitis · Phase 4
- Migraine Disorders · Phase 4
- Molar, Third · Phase 4
- Mucocutaneous Lymph Node Syndrome · Phase 1
- Multiple Myeloma · Phase 4
- Multiple Organ Failure · Phase 4
- Multiple Sclerosis, Chronic Progressive · Phase 3
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Muscle Weakness · Phase 4
- Muscular Diseases · Phase 1
- Muscular Dystrophy, Duchenne · Phase 1/Phase 2
- Myalgia · Phase 4
- Myasthenia Gravis · Phase 1
- Mycobacterium · Phase 3
- Myelitis · Phase 4
- Myelitis, Transverse · Phase 3
- Myelodysplastic-Myeloproliferative Diseases · Phase 2
- Myelodysplastic Syndromes · Phase 2/Phase 3
- Myeloproliferative Disorders · Phase 2
- Myocardial Reperfusion Injury · Phase 2
- Myocarditis · Phase 2
- Myocardium · Phase 2
- Myopathies, Structural, Congenital · Phase 1/Phase 2
- Nasal Obstruction · Phase 4
- Nasal Polyps · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Necrosis · Phase 2
- Neonatology · Phase 2
- Neoplasm Metastasis · Phase 2/Phase 3
- Neoplasms · Phase 3
- Nerve Fibers · Early Phase 1
- Nervous System Diseases · Phase 2
- Neuralgia · Phase 3
- Neuritis · Phase 4
- Neuroblastoma · Phase 2
- Neuroinflammatory Diseases · Phase 2
- Neuromyelitis Optica · Phase 4
- Neurosurgery · Phase 4
- Neutropenia · Phase 2
- No-Reflow Phenomenon · Phase 2
- Occipital Lobe · Phase 4
- Opioid-Related Disorders · Early Phase 1
- Optic Neuritis · Phase 4
- Optic Neuropathy, Ischemic · Phase 3
- Organ Dysfunction Scores · Phase 4
- Oropharyngeal Neoplasms · Phase 1/Phase 2
- Orthopedic Procedures · Phase 4
- Osteoarthritis, Hip · Phase 4
- Osteoarthritis, Knee · Phase 4
- Out-of-Hospital Cardiac Arrest · Phase 2
- Ovarian Hyperstimulation Syndrome · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Pain · Phase 3
- Pain Management · Phase 4
- Papillary Muscles · Phase 2
- Paraneoplastic Polyneuropathy · Phase 2
- Paraparesis, Tropical Spastic · Phase 3
- Paresthesia · Phase 4
- Parkinson Disease · Phase 2
- Patient Satisfaction · Phase 3
- Peripheral Arterial Disease · Phase 4
- Peripheral Nerve Injuries · Phase 1
- Peritoneal Neoplasms · Phase 2
- Pharmacological and Toxicological Phenomena · Phase 2
- Pharmacology · Early Phase 1
- Physiology · Phase 1
- Plasmacytoma · Phase 2
- Pneumocystis · Phase 3
- Pneumonia · Phase 3
- Pneumonia, Bacterial · Phase 3
- Pneumonia, Pneumocystis · Phase 4
- Pneumonia, Ventilator-Associated · Phase 2
- Pneumonia, Viral · Phase 3
- Polyarteritis Nodosa · Phase 4
- Post-Cardiac Arrest Syndrome · Phase 2
- Postoperative Complications · Phase 4
- Postoperative Nausea and Vomiting · Phase 4
- Postoperative Pain · Phase 4
- Precancerous Conditions · Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 3
- Pregnancy Complications · Early Phase 1
- Primary Myelofibrosis · Phase 2
- Prostatic Neoplasms · Phase 3
- Proteinuria · Phase 2
- Psychophysiologic Disorders · Phase 3
- Psychotic Disorders · Phase 2
- Pudendal Neuralgia · Phase 4
- Pulmonary Disease, Chronic Obstructive · Phase 4
- Pulpitis · Phase 3
- Purpura · Phase 2
- Purpura, Thrombocytopenic, Idiopathic · Phase 3
- Purpura, Thrombotic Thrombocytopenic · Phase 3
- Quality of Life · Phase 4
- Radiation Oncology · Phase 2
- Radiculopathy · Phase 3
- Raynaud Disease · Early Phase 1
- Receptors, Antigen, T-Cell, alpha-beta · Phase 2
- Recurrence · Phase 3
- Remission Induction · Phase 3
- Remission, Spontaneous · Phase 2
- Renal Dialysis · Phase 4
- Renal Insufficiency · Phase 4
- Renal Insufficiency, Chronic · Phase 4
- Renal Replacement Therapy · Phase 4
- Reperfusion Injury · Phase 2
- Respiratory Distress Syndrome · Phase 3
- Rhabdomyosarcoma · Phase 2
- Rhinitis, Allergic · Phase 4
- Rhinitis, Allergic, Seasonal · Phase 4
- Rituximab · Phase 3
- Rotator Cuff Injuries · Phase 3
- Sarcoma · Phase 2
- Schizophrenia · Phase 3
- Sciatica · Phase 4
- Scleroderma, Systemic · Phase 3
- Sclerosis · Phase 2/Phase 3
- Seizures · Phase 1/Phase 2
- Sepsis · Phase 4
- Severe Acute Respiratory Syndrome · Phase 3
- Severe Fever with Thrombocytopenia Syndrome · Phase 4
- Sezary Syndrome · Phase 2
- Shoulder Impingement Syndrome · Phase 4
- Shoulder Injuries · Phase 4
- Shoulder Pain · Phase 4
- Sinusitis · Phase 4
- Skin Neoplasms · Phase 2
- Sleep Apnea, Obstructive · Phase 4
- Sleep Disorders, Intrinsic · Phase 4
- Spasms, Infantile · Phase 2/Phase 3
- Spinal Cord Diseases · Phase 3
- Spinal Cord Injuries · Phase 3
- Spinal Fusion · Phase 4
- Spinal Stenosis · Phase 3
- Spondylarthropathies · Phase 2
- Spondylitis, Ankylosing · Phase 2
- Spondylosis · Phase 4
- Squamous Cell Carcinoma of Head and Neck · Phase 1/Phase 2
- Squamous Intraepithelial Lesions · Phase 2
- ST Elevation Myocardial Infarction · Phase 2
- Steroids · Phase 4
- Stiff-Person Syndrome · Phase 1/Phase 2
- Stress, Physiological · Phase 4
- Stroke · Phase 4
- Sugammadex · Phase 4
- Surgical Wound Infection · Phase 3
- Systemic Inflammatory Response Syndrome · Phase 4
- Telomere · Phase 2
- Temporomandibular Joint · Phase 4
- Tendinopathy · Phase 4
- Tendon Injuries · Phase 2
- Tennis Elbow · Phase 3
- Tenosynovitis · Phase 4
- Testicular Neoplasms · Phase 2
- Therapeutic Equivalency · Phase 1
- Therapeutics · Phase 2/Phase 3
- Thoracic Surgery · Early Phase 1
- Thrombocytopenia · Phase 3
- Thrombosis · Phase 2
- Thymoma · Phase 2
- Thyroid Gland · Phase 4
- Toxic Optic Neuropathy · Phase 2/Phase 3
- Tracheal Stenosis · Phase 2
- Transplantation · Phase 4
- Trigger Finger Disorder · Phase 4
- Trismus · Phase 2/Phase 3
- Tuberculosis, Meningeal · Phase 3
- Ultrasonography · Phase 4
- Urinary Tract Infections · Phase 3
- Urological Manifestations · Phase 2
- Vasculitis · Phase 4
- Vasculitis, Leukocytoclastic, Cutaneous · Phase 2
- Vestibular Neuronitis · Phase 3
- Waldenstrom Macroglobulinemia · Phase 2
- Wilms Tumor · Phase 2
Mechanism of action
- Glucocorticoid receptorAGONIST
NR3C1 agonist
Combination products
neo-medrol acetate
with neomycin
Approval history
- approvedOct 24, 1957
Chemistry & pharmacology
Loading structure…
SMILES
CC(=O)OCC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C[C@H](C)C4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@@]21C- Mol. weight
- 416.51 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral, Topical
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
Yes
Sources
- NCATSX4W7ZR7023 ↗
- ChEMBLCHEMBL1364144 ↗
- WikipediaMethylprednisolone ↗
- ChEMBLCHEMBL1697783 ↗
- ChEMBLCHEMBL1697782 ↗
- ChEMBLCHEMBL1531134 ↗
- ChEMBLCHEMBL650 ↗
- ChEMBLCHEMBL1201265 ↗
- ChEMBLCHEMBL1201081 ↗
- ChEMBLCHEMBL1200844 ↗
- ChEMBLCHEMBL2106453 ↗
- ChEMBLCHEMBL2105359 ↗
Also known as
- 1-dehydro-6alpha-methylhydrocortisone
- 1-dehydro-6alpha-methylhydrocortisone
- 1-dehydro-6α-methylhydrocortisone
- 1-dehydro-6α-methylhydrocortisone
- 2b3-201
- 4'-fluor-4-(4-methylpiperidino)-butyrophenone
- (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
- 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione
- 6alpha-methylprednisolone aceponate
- 6-alpha-methylprednisone
- 6-alpha-methylprednisone
- (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- (6α,11β)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione
- acetyl-methylprednisolone
- advantan
- advantan
- advantan
- advantan
- adventan
- buronil
- csl brand of methylprednisolone aceponate
- delta(1)-6alpha-methylhydrocortisone
- delta(1)-6alpha-methylhydrocortisone
- depemedrone
- depmedalone
- depmedalone
- depomedrol
- depo medrol
- depo medrol
- depo-medrol
- depo-medrol
- depo-medrol
- depomedrone
- depomedrone
- depo-medrone
- depo-medrone
- depo-medrone
- depo-methylprednisolone
- eunerpan
- eunerpan
- fg-5111
- fg-5111
- flubuperone
- flubuperone
- flubuperone
- harmosin
- italfarmaco brand of methylprednisolone aceponate
- lexxema
- libernal
- medralone
- medrate
- medrate
- medrol
- medrol
- medrol
- medrol acetate
- medrol acetate
- medrol acetate
- medrone
- medrone
- medrone
- melneurin
- melperomerck
- melperon
- melperon abz
- melperon al
- melperon azu
- melperon beta
- melperone
- melperone
- melperone
- melperone
- melperone
- melperone
- melperone
- melperone
- melperon fg 5111
- melperon-neuraxpharm
- melperon-ratiopharm
- melperon-rph
- melperon stada
- melperon-teva
- melperon von ct
- mel-puren
- methylenprednisolone
- methylenprednisolone
- methylorednisolone
- methylperon
- methylperone
- methylprednisolon
- methylprednisolon
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone
- methylprednisolone 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate)
- methylprednisolone-21-acetate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methylprednisolone aceponate
- methyl prednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate
- methylprednisolone acetate, (11beta,16alpha)-isomer
- methylprednisolone acetate, (11beta,16beta)-isomer
- methylprednisolone hemisuccinate
- methylprednisolone hemisuccinate
- methylprednisolone hemisuccinate
- methylprednisolone sodium succinate
- methylprednisolone sodium succinate
- methylprednisolone sodium succinate
- methylprednisolone sodium succinate
- methylprednisolone succinate
- methylprednisolone succinate
- methylprednisolone succinate
- methylprednisolone succinate
- methylprednisolone succinate
- methylprednisolone succinate
- methylprednisolone suleptanate
- methylprednisolone suleptanate
- methylprednisolone suleptanate
- methylprednisolone suleptanate
- methylprednisolone suleptanate
- methylprednisolone suleptanate
- methylprednisolone suleptanate sodium
- methylprednisolone suleptanate sodium salt
- methylprednisolonum
- methylprednisolonum
- methylprednisone
- methylprednisone
- methylprednisone
- methylprednisone
- methylprenisolone
- methylprenisolone
- methyprednislone
- methyprednisolone
- methyprednisolone
- metilbetasone
- metilprednisolona
- metilprednisolona
- metylperon
- metylperon hydrochloride
- mpso
- neo-medrone
- pnu-67590a
- schering brand of methylprednisolone aceponate
- solomet
- solomet
- solumedrol
- solumedrol
- solu-medrol
- solu-medrol
- u 67590a
- u-67590a
- u-67590a
- u-67590a
- u-67,590a
- urbason
- urbason
- urbasone
- urbasone
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07075315 | Phase 3 | Jan 31, 2028 | Indian Council of Medical Research, Institute of Liver and Biliary Sciences, India |
| NCT07072585 | Phase 2/Phase 3 (Phase 3) | Mar 30, 2026 | National Cancer Institute (NCI) |
| NCT07245355 | N/A | Feb 1, 2026 | Suleyman Demirel University |
| NCT07267650 | N/A | Jan 1, 2026 | Turgutlu State Hospital |
| NCT07211399 | Early Phase 1 (Phase 1) | Jan 1, 2026 | University of Pittsburgh |
| NCT07258771 | Phase 4 | Dec 31, 2025 | AbbVie, University of Michigan |
| NCT07265258 | Phase 4 | Dec 30, 2025 | Innovent Biologics (Suzhou) Co. Ltd. |
| NCT07287397 | Phase 1/Phase 2 (Phase 2) | Dec 18, 2025 | Vector Y Therapeutics |
| NCT07208799 | Phase 2 | Dec 1, 2025 | Nishtar Medical University, University of Health Sciences Lahore |
| NCT07255248 | N/A | Nov 17, 2025 | Harvard University |
| NCT07054801 | Phase 2 | Nov 1, 2025 | University of California, San Francisco |
| NCT07270549 | Phase 1/Phase 2 (Phase 2) | Nov 1, 2025 | CTNNB1 Foundation, University of Ljubljana |
| NCT07175649 | N/A | Oct 31, 2025 | Sun Yat-Sen University |
| NCT07158476 | Phase 4 | Oct 21, 2025 | St. Louis University |
| NCT07187037 | N/A | Oct 1, 2025 | Konya City Hospital |
| NCT07185633 | Phase 2 | Oct 1, 2025 | Soochow University |
| NCT07180277 | Phase 4 | Oct 1, 2025 | Zhangjiagang First People's Hospital |
| NCT07101445 | Phase 4 | Sep 24, 2025 | Emory University, Gamida Cell, National Cancer Institute (NCI) |
| NCT07175623 | N/A | Sep 16, 2025 | Konya City Hospital |
| NCT07052929 | Phase 1/Phase 2 (Phase 2) | Sep 11, 2025 | Astellas |
Showing 20 of 907 trials
Page 1 / 46
Organizations
Research & Development (665)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 63 | 16 | 5 | 1993 |
| University of Copenhagen | Academic/Hospital | 31 | 30 | 4 | 1995 |
| Roche | For profit | 29 | 20 | 3 | 1999 |
| University of Texas at Houston | Academic/Hospital | 26 | 21 | 5 | 1993 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 24 | 18 | 4 | 1999 |
| Capital Medical University | Academic/Hospital | 23 | 19 | 5 | 2010 |
| Novartis | For profit | 20 | 14 | 3 | 2002 |
| Harvard University | Academic/Hospital | 19 | 13 | 5 | 1994 |
| Northwestern University | Academic/Hospital | 17 | 15 | 5 | 1997 |
| Sun Yat-Sen University | Academic/Hospital | 17 | 16 | 5 | 2007 |
| Pfizer | For profit | 14 | 8 | 4 | 2003 |
| Astellas | For profit | 13 | 13 | 3 | 1999 |
| Emory University | Academic/Hospital | 13 | 8 | 3 | 2006 |
| Genentech | For profit | 13 | 8 | 2 | 1998 |
| University of Minnesota | Academic/Hospital | 13 | 13 | 3 | 1996 |
| Bristol-Myers Squibb | For profit | 10 | 3 | 3 | 2008 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 10 | 3 | 4 | 1994 |
| People's Liberation Army of China | Government | 10 | 7 | 5 | 2011 |
| Assistance Publique - Hôpitaux de Paris | Academic/Hospital | 9 | 9 | 3 | 2018 |
| Biogen | For profit | 9 | 7 | 2 | 2003 |
665 organizations
Page 1 / 34
Marketing (56)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abbott | For profit | MKTG | Feb 22, 1991 |
| Abraxis | For profit | MKTG | Jun 8, 1984 |
| Akorn, Inc. | For profit | MKTG | — |
| Amneal Pharmaceuticals | For profit | SYN | Nov 9, 2016 |
| Amneal Pharmaceuticals | For profit | MKTG | May 20, 2019 |
| Athenex, Inc. | For profit | MKTG | — |
| Aurobindo Pharma | For profit | MKTG | Dec 15, 2015 |
| Bedford Pharmaceuticals | For profit | MKTG | Feb 21, 2007 |
| Belmar Pharmacy | For profit | MKTG | Dec 6, 1979 |
| Bristol-Myers Squibb | For profit | MKTG | Jan 21, 2022 |
| Caplin Point Laboratories | For profit | MKTG | Jan 26, 2026 |
| Chartwell Pharmaceuticals | For profit | MKTG | Feb 22, 2019 |
| Duramed Research | For profit | MKTG | Feb 21, 1984 |
| Elkins Sinn | For profit | MKTG | Feb 15, 1980 |
| Endo Pharmaceuticals | For profit | MKTG | Dec 22, 1998 |
| Eu Yan Sang | For profit | MKTG | Feb 23, 2005 |
| Eugia Pharma | For profit | MKTG | Dec 15, 2015 |
| Fresenius | For profit | MKTG | Jul 30, 2004 |
| Heather Pharma | For profit | MKTG | — |
| Hikma | For profit | MKTG | Feb 16, 2016 |
| Hospira | For profit | MKTG | Mar 28, 1978 |
| Hospira | For profit | SYN | Nov 25, 2008 |
| Ingenus Pharmaceuticals | For profit | MKTG | Jan 9, 2019 |
| International Medication | For profit | MKTG | — |
| Invatech | For profit | MKTG | Jul 28, 1981 |
| Jubilant Innovation Ltd. | For profit | MKTG | Oct 31, 1997 |
| Lupin | For profit | MKTG | Feb 22, 2019 |
| Nichi-Iko Pharmaceutical Co., Ltd. | For profit | MKTG | Jun 27, 2018 |
| Novartis | For profit | MKTG | Oct 31, 1997 |
| Novast Labs | For profit | MKTG | Jan 9, 2019 |
| Organon | For profit | MKTG | Jun 25, 1982 |
| PH HEALTH | For profit | MKTG | Dec 22, 1998 |
| Par Pharmaceuticals | For profit | SYN | Jan 21, 2022 |
| Par Pharmaceuticals | For profit | MKTG | Apr 25, 1988 |
| Pfizer | For profit | MKTG | Oct 24, 1957 |
| Pfizer | For profit | NDA2 | Oct 24, 1957 |
| Pharmacia & Upjohn | For profit | NDA2 | Oct 24, 1957 |
| Pharmacia & Upjohn | For profit | NDA | Oct 24, 1957 |
| Pharmacia & Upjohn | For profit | MKTG | Dec 7, 1964 |
| Praxgen Pharma | For profit | MKTG | Jun 27, 2019 |
| Praxgen Pharma | For profit | MKTG | Jun 27, 2019 |
| RiconPharma | For profit | MKTG | Jan 9, 2019 |
| Rising Pharmaceuticals | For profit | MKTG | Jul 28, 1981 |
| Sagent Pharmaceuticals, Inc. | For profit | MKTG | Jun 27, 2018 |
| Sagent Pharmaceuticals, Inc. | For profit | SYN | Jul 18, 2011 |
| Sandoz | For profit | SYN | Jan 29, 2009 |
| Sandoz | For profit | MKTG | Jul 28, 1981 |
| Slayback Pharma Llc | For profit | MKTG | Jan 3, 2023 |
| Teva | For profit | MKTG | Feb 23, 2005 |
| Teva | For profit | SYN | Nov 30, 1992 |
| Tianjin Kingyork | For profit | MKTG | Apr 20, 2021 |
| Tianjin Tianyao Pharmaceuticals | For profit | MKTG | May 14, 2018 |
| Vintage | For profit | MKTG | Dec 22, 1998 |
| Watson Pharmaceuticals | For profit | MKTG | Feb 9, 1982 |
| Wilshire Pharmaceuticals | For profit | MKTG | Jan 3, 2023 |
| Zydus Discovery DMCC | For profit | MKTG | Apr 23, 2018 |